Want to see HK:7630 full AI Analyst Report?
7630 Stock Chart & Stats
$11.72
-$0.23(-1.92%)
―
--
Day’s Range― - ―
52-Week Range$10.31 - $47.98
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.07M
Market Cap
HK$3.38B
Enterprise Value$7.65K
Total Cash (Recent Filing)HK$156.99M
Total Debt (Recent Filing)HK$623.31K
Price to Earnings (P/E)―
Beta-1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding282,461,520
10 Day Avg. Volume1,861,551
30 Day Avg. Volume1,073,258
Financial Highlights & Ratios
PEG Ratio2.15
Price to Book (P/B)-10.84
Price to Sales (P/S)278.67
P/FCF Ratio-109.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$37.60Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Oncology PipelineA focused oncology strategy gives the company a clear therapeutic direction and the potential to build differentiated products around targeted cancer treatment. Small-molecule development can support multiple indications and future commercialization opportunities if clinical programs demonstrate durable efficacy.
Strong Gross MarginConsistently high gross margins indicate attractive underlying unit economics for the products currently reported. If revenue expands through successful development or commercialization, this margin profile could provide operating leverage and allow a greater share of incremental sales to support research investment and eventual profitability.
Improving 2025 Cash BurnThe reduction in free-cash-flow burn during 2025 is a constructive sign that management has made progress controlling cash outflows. Although operations remain cash-consuming, continued improvement would extend financial runway, reduce dependence on external funding, and provide more flexibility for advancing oncology programs.
Bears Say
Negative Equity And Rising DebtNegative equity reflects accumulated losses and leaves the company with a weak capital cushion. The subsequent increase in debt raises financial risk and reduces flexibility, while future funding needs could create refinancing pressure or require additional capital that may dilute existing shareholders.
Large Operating And Net LossesLarge and widening operating losses show that the current cost base is not supported by reported revenue. Continued losses can consume capital, constrain investment in the development pipeline, and make the path to self-sustaining profitability dependent on a substantial improvement in revenue or spending efficiency.
Volatile And Depressed RevenueThe sharp post-2023 revenue decline and still-low 2025 base indicate limited consistency in the company’s commercial revenue stream. This volatility makes planning and resource allocation harder, weakens operating leverage, and leaves the business more reliant on financing while oncology programs progress.
IMPACT Therapeutics, Inc. Class H News
7630 FAQ
What was IMPACT Therapeutics, Inc. Class H’s price range in the past 12 months?
IMPACT Therapeutics, Inc. Class H lowest stock price was $10.31 and its highest was $47.98 in the past 12 months.
What is IMPACT Therapeutics, Inc. Class H’s market cap?
IMPACT Therapeutics, Inc. Class H’s market cap is HK$3.38B.
When is IMPACT Therapeutics, Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IMPACT Therapeutics, Inc. Class H’s earnings last quarter?
Currently, no data Available
Is IMPACT Therapeutics, Inc. Class H overvalued?
According to Wall Street analysts IMPACT Therapeutics, Inc. Class H’s price is currently Undervalued.
Does IMPACT Therapeutics, Inc. Class H pay dividends?
IMPACT Therapeutics, Inc. Class H does not currently pay dividends.
What is IMPACT Therapeutics, Inc. Class H’s EPS estimate?
IMPACT Therapeutics, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IMPACT Therapeutics, Inc. Class H have?
IMPACT Therapeutics, Inc. Class H has 282,461,520 shares outstanding.
What happened to IMPACT Therapeutics, Inc. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IMPACT Therapeutics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:7630
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IMPACT Therapeutics, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
178.20%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
IMPACT Therapeutics, Inc. Class H
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
7630 Stock 12 Month Forecast
Average Price Target
$37.60
Technical Analysis
Ascletis Pharma, Inc.
―
CanSino Biologics, Inc. Class H
―
Nanjing Leads Biolabs Co., Ltd. Class H
―
Genfleet Therapeutics (Shanghai), Inc. Class H
―
LongBio Pharma (Suzhou) Co., Ltd. Class H
―